Vincent Gattullo, former Chairman, President and CEO of APDA Posted on September 13, 2017September 14, 2017 by Nancy Braun It is with deep sadness that we share the news that Vincent Gattulo, our former Chairman, President and CEO who passionately served the organization and the Parkinson’s community for more than thirty years, passed away on September 12, 2017. Mr. Gattullo began his service to APDA in 1986, first as a member of the Board […]Read More
EXCITING PARKINSON’S DISEASE TREATMENT NEWS Posted on August 28, 2017August 29, 2017 by Nancy Braun New York, NY, August 28, 2017 – The American Parkinson Disease Association is pleased to share with the Parkinson’s community the arrival of a new medication in the treatment arsenal to address Parkinson’s symptoms. Approved August 24 by the U.S. Food and Drug Administration is GOCOVRI™ (amantadine) developed by Adamas. GOCOVRI is an extended release […]Read More
Archived Webinar: Psychiatric Manifestations of Parkinson’s Disease Posted on July 6, 2017July 27, 2017 by css-admin ARCHIVED: Free Webinar Hosted by University at Albany Aired on: Thursday, July 20, 2017 Watch Here University at Albany hosted a free live webcast for medical and public health professionals, featuring guest speaker Guy J. Schwartz, MD, the Assistant Clinical Professor of Neurology at Stony Brook University Medical Center. In depth, Guy discussed the psychiatric symptoms […]Read More
Nationwide Movement to Help End Parkinson Disease: 2017 APDA Optimism Walk Series Launches to Raise Critical Funds and Awareness Posted on April 4, 2017June 8, 2017 by Nancy Braun Thousands Will Walk and Fundraise to Help People with Parkinson’s Live Life to the Fullest New York, NY, April 3, 2017 – With the launch of Parkinson’s Disease Awareness Month, the American Parkinson’s Disease Association (APDA) officially announces the schedule for the 2017 Optimism Walks — a nationwide movement to mobilize and inspire people to step […]Read More
Eighty-Seven Organizations Call on Congress to Protect Medicaid Posted on March 22, 2017June 8, 2017 by Nancy Braun Source: Original Press Release through BusinessWire on March 20, 2017 04:28 PM Eastern Daylight Time BETHESDA, Md.–(BUSINESS WIRE)–Eighty-seven organizations issued a letter today calling on Congress to take a hard look at the likely significant and life-threatening consequences of the American Health Care Act on millions of patients. The organizations represent Americans with complex health […]Read More
Make Every Step Count at the 2017 Parkinson’s Unity Walk Posted on March 13, 2017March 13, 2017 by Nancy Braun Join us at the 2017 Parkinson’s Unity Walk on April 22nd. 100% of donations support research funded by six major Parkinson’s foundations. Learn more at UnityWalk.org. Share this page:Read More
World Parkinson Congress 2016 Posted on March 6, 2017 by css-admin 2016 World Parkinson Congress Leadership Forum Before the 4th World Parkinson Congress officially kicked-off in Portland, Oregon nearly 200 Parkinson’s Organizational Partners gathered to network and learn from each other at the first ever WPC Leadership Forum. The Forum allowed PD Advocacy Leaders to talk about their outreach, fundraising, and educational efforts and to strategize […]Read More
APDA Funded Researcher Published in Journal of Neuroscience – July 2016 Posted on March 6, 2017March 10, 2017 by css-admin APDA funded researcher published in Journal of Neuroscience – July 2016 APDA funded research demonstrates that alpha-synuclein inclusion formation in neurons can be blocked and that novel therapeutic compounds targeting this process by inhibiting LRRK2 kinase activity may slow progression of PD-associated pathology. In 2013 and 2014, APDA awarded research grants to Laura Vopicelli-Daley, PhD, […]Read More
ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) is now available Posted on March 6, 2017June 29, 2017 by css-admin The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis is now available through NUPLAZIDconnect™ Patient Access and Support Services The American Parkinson Disease Association is pleased to share the news that ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address […]Read More
FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) Posted on March 6, 2017March 6, 2017 by css-admin FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis U.S. Commercial Launch Planned for June 2016 The American Parkinson Disease Association is pleased to share the news that ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative […]Read More
